Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Palbociclib plus endocrine therapy significantly enhances overall survival of HR +/ HER2 ‐ metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting‐a large institutional study

(2022) Min Jin Ha et al.   INTERNATIONAL JOURNAL OF CANCER

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

(2022) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies

(2021) Nadia Harbeck et al.   Future Oncology

Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States

(2021) Qianyi Zhang et al.   HEALTH SERVICES RESEARCH

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

(2021) G.N. Hortobagyi et al.   ANNALS OF ONCOLOGY

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

(2021) Adam Brufsky et al.   Targeted Oncology

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review

(2021) Gebra Cuyún Carter et al.   Cancer Management and Research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making

(2021) Paul Cottu et al.   BREAST

The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation

(2021) Peter K Honig   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies

(2021) Donna R. Rivera et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study

(2021) Katie Mycock et al.   Future Oncology

Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer

(2021) Xiaoliang Wang et al.   VALUE IN HEALTH

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

(2021) James Sun et al.   Cancer Medicine

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer

(2020) Cynthia Huang Bartlett et al.   PLoS One

Assessing New Drugs in Advanced Cancer: Beyond Randomised Evidence

(2020) D. Dodwell et al.   CLINICAL ONCOLOGY

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

(2019) H. S. Rugo et al.   BREAST CANCER RESEARCH AND TREATMENT

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

(2019) Jing Xi et al.   Journal of the National Comprehensive Cancer Network

Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy

(2019) Leticia Varella et al.   BREAST CANCER RESEARCH AND TREATMENT

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint

(2018) Melissa D. Curtis et al.   HEALTH SERVICES RESEARCH

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

(2018) Anna Forsythe et al.   Cancer Management and Research

Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study

(2018) Gavin Taylor-Stokes et al.   BREAST

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

(2017) Amr Makady et al.   PHARMACOECONOMICS

Real-world Data for Clinical Evidence Generation in Oncology

(2017) Sean Khozin et al.   JNCI-Journal of the National Cancer Institute

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2016) A. J. Walker et al.   CLINICAL CANCER RESEARCH

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

A Primer on Effectiveness and Efficacy Trials

(2014) Amit G Singal et al.   Clinical and Translational Gastroenterology

The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments

(2013) Peter C. Austin   STATISTICS IN MEDICINE

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute